Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Netherlands Journal of Medicine

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 28276325
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Iron-deficiency anemia.

  2015cited by this paper
• Severe hypophosphataemia after intravenous iron administration.

  2014cited by this paper
• Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease

  2014cited by this paper
• Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.

  2014cited by this paper
• FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia

  2014cited by this paper
• Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.

  2013cited by this paper
• Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation.

  2013cited by this paper
• Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study

  2013cited by this paper
• Comparative Review of the Safety and Efficacy of Ferric Carboxymaltose Versus Standard Medical Care for the Treatment of Iron Deficiency Anemia in Bariatric and Gastric Surgery Patients

  2013cited by this paper
• Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women

  2013cited by this paper
• A multicenter, randomized, active‐controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia

  2013cited by this paper
• Ferric Carboxymaltose

  2012cited by this paper
• Fibroblast growth factor 23: state of the field and future directions.

  2012cited by this paper
• Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation

  2011cited by this paper
• Fibroblast growth factor-23 and Klotho in chronic kidney disease

  2011cited by this paper
• Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data

  2011cited by this paper
• Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

  2011cited by this paper
• A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients

  2010cited by this paper
• Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient.

  2010cited by this paper
• Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia

  2009cited by this paper
• Ferric Carboxymaltose A Review of its Use in Iron-Deficiency Anaemia

  2009cited by this paper
• Determination of fibroblast growth factor 23

  2009cited by this paper
• A new equation to estimate glomerular filtration rate.

  2009cited by this paper
• BLOOD MANAGEMENT: Large‐dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial

  2009cited by this paper
• Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.

  2009cited by this paper
• Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis

  2009cited by this paper
• FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.

  2009cited by this paper
• Vitamin D status: measurement, interpretation, and clinical application.

  2009cited by this paper
• Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

  2008cited by this paper
• Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation.

  2008cited by this paper
• Tertiary ‘Hyperphosphatoninism’ Accentuates Hypophosphatemia and Suppresses Calcitriol Levels in Renal Transplant Recipients

  2007cited by this paper
• Bone disease after renal transplantation.

  2006cited by this paper
• Post-renal transplantation hypophosphatemia: a review and novel insights

  2006cited by this paper
• Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?

  2006cited by this paper
• Osteoporosis after solid organ transplantation.

  2005cited by this paper
• VITAMIN D IN HEALTH AND DISEASE: The Evolution of Assays for Parathyroid Hormone

  2005cited by this paper
• A simplified method for inorganic phosphate determination and its application for phosphate analysis in enzyme assays.

  2003cited by this paper
• Bone disease after renal transplantation.

  2003cited by this paper
• Immunoassays for the detection of parathyroid hormone.

  2002cited by this paper
• The evolution of assays for parathyroid hormone

  2001cited by this paper
• Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy.

  1998cited by this paper
• IRON DEFICIENCY ANEMIA

  1998cited by this paper
• Vitamin D Metabolism and the Clinical Aspects of Measuring Metabolites

  1994cited by this paper
• Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1,25-dihydroxycholecalciferol.

  1986cited by this paper
• Enzymic creatinine assay: a new colorimetric method based on hydrogen peroxide measurement.

  1983cited by this paper

• Anemia and iron deficiency in post-kidney transplantation: an unsolved challenge

  2025cites this paper
• UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease

  2025cites this paper
• Expert recommendations for the management of iron deficiency in patients with heart failure in Asia.

  2024cites this paper
• Treatment Options for Anemia in Kidney Transplant Patients: A Review

  2023cites this paper
• Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?

  2022cites this paper
• High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment

  2022cites this paper
• [A complex case of renal phosphate wasting…].

  2021cites this paper
• Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review

  2021cites this paper
• Kronik böbrek hastalarında ferrik karboksimaltoz tedavisinin serum fosfor düzeyine etkisi

  2021cites this paper
• Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety

  2021cites this paper
• Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review

  2020cites this paper
• Improving the safety of intravenous iron treatments for patients with chronic kidney disease

  2020cites this paper
• Iron deficiency after kidney transplantation

  2020cites this paper
• TCRM_A_243462 245..259

  2020cites this paper